R&D Projects

Confirmed projects database queries

The information may be unavailable due to the results not being approved or confirmed. In particular, when a call includes regions where projects are cofunded by EC funds and others where that is not the case, confirmation or approval may be not simultaneous.

Call for SR&TD Project Grants - 2017

Medicinal Chemistry

PTDC/MED-QUI/28721/2017: Delivery vehicles of therapeutic gasotransmitters NO and H2S based on nanoporous materials. Moisés Luzia Gonçalves Pinto, Associação do Instituto Superior Técnico para a Investigação e o Desenvolvimento (IST-ID). €227,943.
PTDC/MED-QUI/28764/2017: Intracellular Drug Delivery using Small Molecule Drug Conjugates for Prostate Cancer Therapy. Gonçalo Bernardes, Instituto de Medicina Molecular João lobo Antunes (IMM/FM/ULisboa). €239,960.
PTDC/MED-QUI/28800/2017: Identification of New Drugs for Cystic Fibrosis. Margarida Sofia Pereira Duarte Amaral, FCiências.ID - Associação para a Investigação e Desenvolvimento de Ciências (Fciências.ID). €237,378.
PTDC/MED-QUI/29036/2017: Targeting multi-resistant tuberculosis with new potent isoniazid derivatives: an integrated medicinal chemistry approach. Filomena Elisabete Lopes Martins Elvas Leitão, FCiências.ID - Associação para a Investigação e Desenvolvimento de Ciências (Fciências.ID). €226,021.
PTDC/MED-QUI/29649/2017: Multifunctional Nanoseeds for Chemoradiotherapy of Glioblastoma. António Paulo, Associação do Instituto Superior Técnico para a Investigação e o Desenvolvimento (IST-ID). €237,212.
PTDC/MED-QUI/29712/2017: Targeting aromatic amino acid hydroxylases (AAAHs) to modulate disrupted homeostasis of catecholamines, serotonin and melatonin. Ana Paula Costa Santos Peralta Leandro, FARM-ID, Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento (FARM-ID). €231,167.
PTDC/MED-QUI/29800/2017: Sensitization of urologic tumors therapy driven by nanotechnology. RUI Manuel de MEDEIROS Melo Silva MEDEIROS, Instituto Português de Oncologia do Porto Francisco Gentil, EPE (IPO Porto). €239,938.
PTDC/MED-QUI/30021/2017: A multitarget strategy to hit all stages of the Plasmodium life-cycle. Rui Moreira, FARM-ID, Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento (FARM-ID). €239,872.
PTDC/MED-QUI/30591/2017: Tackling multidrug resistance in cancer: plant-derived lead compounds as P-glycoptrotein (P-gp) and breast cancer resistant protein (BCRP) modulators and collateral sensitivity agents. Maria José Umbelino Ferreira, FARM-ID, Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento (FARM-ID). €227,725.
PTDC/MED-QUI/31468/2017: Tricks or Treats? Toward Selective Organoruthenium(II) Glycoconjugated Anticancer Agents. Pedro Ricardo da Rocha Florindo, FARM-ID, Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento (FARM-ID). €236,720.
PTDC/MED-QUI/31721/2017: NANOFORMULATED HYBRID MOLECULES FOR SPECIFIC TAREGETING MELANOMA METASTASIS. Maria Manuela de Jesus Guilherme Gaspar, FARM-ID, Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento (FARM-ID). €222,450.